argenx SE Files Form 6-K
Ticker: ARGX · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1697862
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, regulatory-update
TL;DR
argenx SE filed a 6-K on June 30, 2025. Check for updates.
AI Summary
On June 30, 2025, argenx SE issued a press release. The filing is a Form 6-K, which is a report of a foreign private issuer. The company's principal executive offices are located in Amsterdam, the Netherlands.
Why It Matters
This filing indicates that argenx SE, a biopharmaceutical company, has submitted a report to the SEC, which may contain important updates for investors.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not appear to contain significant new financial or operational information.
Key Numbers
- 001-38097 — Commission File Number (Identifies the specific filing with the SEC.)
Key Players & Entities
- ARGENX SE (company) — Registrant
- 001-38097 (dollar_amount) — Commission File Number
- June 30, 2025 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically used to provide information that the company makes or is required to make public in its home country.
When was this Form 6-K filed?
This Form 6-K was filed on June 30, 2025.
What is the company's name and ticker symbol?
The company's name is ARGENX SE. The filing does not explicitly state a ticker symbol, but the Commission File Number is 001-38097.
Where are argenx SE's principal executive offices located?
argenx SE's principal executive offices are located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands.
Does argenx SE file annual reports under Form 20-F or 40-F?
The filing indicates that argenx SE files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding ARGENX SE (ARGX).